9 analysts have shared their evaluations of Nevro (NYSE:NVRO) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 0 | 8 | 1 | 0 |
| Last 30D | 0 | 0 | 2 | 1 | 0 |
| 1M Ago | 0 | 0 | 3 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 2 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.89, a high estimate of $19.00, and a low estimate of $11.00. Highlighting a 17.28% decrease, the current average has fallen from the previous average price target of $18.00.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent analyst actions unveils how financial experts perceive Nevro. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| William Plovanic | Canaccord Genuity | Lowers | Hold | $11.00 | $17.00 |
| Nathan Treybeck | Wells Fargo | Lowers | Equal-Weight | $13.00 | $14.00 |
| Adam Maeder | Piper Sandler | Lowers | Underweight | $12.00 | $15.00 |
| Shagun Singh | RBC Capital | Lowers | Sector Perform | $16.00 | $18.00 |
| Anthony Petrone | Mizuho | Lowers | Neutral | $16.00 | $20.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Equal-Weight | $14.00 | $17.00 |
| Joanne Wuensch | Citigroup | Lowers | Neutral | $16.00 | $18.00 |
| Lawrence Biegelsen | Wells Fargo | Lowers | Equal-Weight | $17.00 | $20.00 |
| Mike Polark | Baird | Lowers | Neutral | $19.00 | $23.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nevro. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nevro compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Nevro's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Nevro's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Nevro analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Nevro's Background
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
Key Indicators: Nevro's Financial Health
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Nevro displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 2.05%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Nevro's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.73% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Nevro's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Nevro's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -1.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.74, Nevro faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Basics of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.